Villere ST Denis J & Co. LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 113.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 141,739 shares of the company’s stock after buying an additional 75,267 shares during the quarter. Johnson & Johnson makes up 1.7% of Villere ST Denis J & Co. LLC’s portfolio, making the stock its 27th biggest holding. Villere ST Denis J & Co. LLC’s holdings in Johnson & Johnson were worth $23,461,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also bought and sold shares of the company. DORCHESTER WEALTH MANAGEMENT Co grew its position in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P grew its position in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. grew its position in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. grew its holdings in Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after buying an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd increased its stake in Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after acquiring an additional 20,528 shares during the last quarter. Hedge funds and other institutional investors own 68.40% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have issued reports on JNJ shares. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 18th. Credit Suisse Group boosted their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Finally, HSBC assumed coverage on Johnson & Johnson in a report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 target price for the company. Nine equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $170.65.
Insiders Place Their Bets
In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Down 0.7 %
Shares of JNJ opened at $155.75 on Monday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $404.79 billion, a price-to-earnings ratio of 31.53, a PEG ratio of 3.15 and a beta of 0.55. The stock’s 50-day moving average price is $165.97 and its 200-day moving average price is $162.29.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter in the prior year, the business earned $2.59 earnings per share. The company’s revenue was up 6.3% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- 3 Fintech Stocks With Good 2021 Prospects
- Will the Energy Sector Continue to Outshine the Market?
- What Are Dividend Contenders? Investing in Dividend Contenders
- MarketBeat Week in Review – 9/25 – 9/29
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- CarMax Slides On Earnings Disappointment, Time To Celebrate?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
